TOKYO -- Japanese drugmaker Daiichi Sankyo is racing to develop Japan's own messenger RNA vaccine, aiming for release by the end of next year, as CEO Sunao Manabe looks beyond COVID to make the technology a pillar of the company's future business.
Interview
Japan's Daiichi Sankyo to make mRNA vaccine pillar of business
CEO hints at using technology for applications other than COVID-19
Daiichi Sankyo CEO Sunao Manabe said, "We are directing all available resources" to the development of the COVID vaccine. (Source photos by Kai Fujii and Kaisuke Ota)
Read Next
Latest on Interview
